Syndax Announces Participation in September Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has announced its participation in two upcoming investor conferences in September 2025.
CEO Michael A. Metzger and the management team will present at Citi's 2025 BioPharma Back to School Conference on September 2 at 4:45 p.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 9:00 a.m. ET. Both presentations will be available via webcast on the company's investor relations website.
Details
News Market Reaction – SNDX
On Aug 26, the day this news came out, SNDX closed 1.21% above the previous close.
Data tracked by StockTitan Argus for the Aug 26 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- Citi’s 2025 BioPharma Back to School Conference with a fireside chat on Tuesday, September 2, 2025, at 4:45 p.m. ET.
- H.C. Wainwright 27th Annual Global Investment Conference with a company presentation on Monday, September 8, 2025, at 9:00 a.m. ET.
A live webcast of these sessions will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.